The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Intravascular hemolysis and the pathophysiology of sickle cell disease
Open accessAbstract
flow, normoxia to hypoxia, isotonic to hypertonic environment, and acidotic to alkalotic milieu.Multiple components contribute to sickle hemoglobinopathy pathophysiology, including primary components arising from HbS polymerization and secondary components that are downstream effects of the HbS polymer. Understanding how these components' complexity is compounded by genetic and environmental modulation provides insight into the well-known clinical heterogeneity of sickle cell disease (SCD).A cardinal feature of SCD pathogenesis involves inflammation, accompanied by heterocellular leukocyte-platelet-erythrocyte-endothelial adhesive events that trigger vaso-occlusive episodes, acute organ ischemia, and reperfusion injury.Twenty-five years ago, epidemiological studies identified leukocytosis, lower HbF levels, and higher total hemoglobin levels as risk factors associated with increasing incidence of acute painful episodes and acute chest syndrome (ACS) (5).The independent association of high total hemoglobin levels with more pain, ACS events, and osteonecrosis was never mechanistically explained; however, it was implied to be a result of increased blood viscosity (Table 1).Recent epidemiological studies found that lower hemoglobin levels and higher intensity of steady-state hemolytic anemia consistently associate with vasculopathic complications of disease, such as stroke, leg ulcers, PH, priapism, and renal failure.This suggests that certain subphenotypes of SCD relate more to hemolytic anemia severity rather than sickle vaso-occlusion.The reader is referred to recent reviews describing the exceptional strides made in understanding the roles of red cell rigidity (6), inflammation, and cell adhesion in sickle vaso-occlusion (7-9).Here, we review the complementary role of intravascular hemolysis and anemia.Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability.Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non-oxygen-binding form of hemoglobin that readily loses heme.Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease.Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis.These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling.Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Once released, IL-1β binds to IL-1 receptor (IL-1R) on leukocytes and vascular cells, promoting a cascade of downstream events that lead to activation of neutrophils and platelets and upregulation of E-selectin, P-selectin, VCAM-1, ICAM-1, and chemokines such as IL-8 in endothelial cells, all of which promote vaso-occlusion (14, 17) (Figure 1).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaso-occlusion contributes to ischemia-reperfusion injury, which, along with release of eDAMPs, promotes the progression of sterile inflammation (Figure 1d) in SCD (14, 17, 18).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies in adults with SCD lend further support to the role of hemolysis by showing a link between the hyperhemolysis phenotype of SCD and stroke risk (17).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Unequal protection by HbF across the gamut of sickle cell disease complications might be partially explained by differences in the pathophysiologic roots of these complications.57,58”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Acute painful episodes and acute chest syndrome are a result of sickle vasoocclusion; HbF has the most noticeable beneficial effect on these subphenotypes.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in Patients with Primary Pulmonary Hypertension
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. Μ., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,488
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“Mortality Increases risk (19, 39, 42, 47, 49, 64, 188) Protective (189) Protective (190)”
Self-citationCerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
Rother, R. P., Bell, L. B., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,565
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationCastro, O. L., Brambilla, D. J., Thorington, B. D., Reindorf, C. A., Scott, R., GILLETTE, P. N., Vera, J., & Levy, P. S. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 805
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1038/nm1202-799 · DOI · Paper page
Cited by
Sorted by citations
Items 601–700 of 746
Bellamy, C. O. C., & Burt, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00015-6
Folh, J., Horton, R. E., Sulague, R. M., & Kpodonu, J. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100355
A Rare Case: HaemoglobinS-Thalassemia in Adult
Luciana, L., & Sukartini, N. (2023) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v29i2.2540
Jamilu, I. A. (2023) · IDOSR JOURNAL OF APPLIED SCIENCES · doi:10.59298/idosr/2023/10.2.1411
Aspectos da angiogênese na anemia falciforme
Fabris, F. C. Z. (2021) · doi:10.47749/t/unicamp.2021.1235645
Le globule rouge drépanocytaire. Données génétiques et structurelles
Galactéros, F. (2023) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(23)01302-4
Ajeigbe, K. O., Adeleye, G. S., Owonikoko, M. W., Adelakun, M. A., Odesanmi, E. O., & Awoyinka, O. A. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i11.41
Prevalence of Asymptomatic Bacteriuria in Children with Sickle Cell Disease
Nassif, A., Ghanem, A., Khori, M., & Chreitah, A. (2024) · International Journal of Medical Science · doi:10.14445/23939117/ijms-v11i1p101
Evaluation of the biological safety of the extract of Senegalia bahiensis (Benth.) Seigler & Ebinger
Santos, E. B., da Silva, N. F., Castanha, E. R., Filho, V. D. M. S., & Falcão, R. E. A. (2024) · Concilium · doi:10.53660/clm-2864-24c42
Barnett, C. F., Brusca, S. B., Kolaitis, N. A., & Marco, T. D. (2024) · Current Respiratory Medicine Reviews · doi:10.2174/011573398x283197240222113135
Ferritin level in sickle cell patients at the sickle cell referral center of Lomé in 2022
Magnang, H., Mawussi, K., Corcellar, W. K. M., Irénée, K., Layibo, Y., Padaro, E., & Fétéké, L. (2024) · International Journal of Blood Transfusion and Immunohematology · doi:10.5348/100082z02mh2024ra
Physiopathologie de la drépanocytose et perspectives thérapeutiques
Allali, S., Pinhas, Y., Maciel, T. T., & Hermine, O. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.03.003
Emerging trends in Sickle cell disease and CRISPR/Caspases
Ababio, G. K. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004305 · Cited by 1
Zheng, M., Xiong, X., Zheng, Z., Liu, C., Wang, X., Luo, S., Xie, Q., Liu, Y., & Chen, Q. (2024) · doi:10.22541/au.171346117.73757852/v1
William, N., & Acker, J. P. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.103929
Uju, C. M., Ulasi, T. O., Ezeudu, C. E., Okpara, H. C., Elo-Ilo, J. C., & Ezenyeaku, C. A. (2023) · Journal of the Nigerian Academy of Medicine · doi:10.4103/jnam.jnam_5_23
Jones, J., Abou-Baker, N., Overholser, L., Hassell, K. L., & Diers, T. (2024) · Springer eBooks · doi:10.1007/978-3-031-54281-7_36
Hadia, R. (2024) · Asian Journal of Pharmaceutics · doi:10.22377/ajp.v18i02.5445
Qu, G., Ribeiro, H. A., Solomon, A. L., Vieira, L. S., Goddard, Y., Diodati, N. G., Lazarte, A. V., Wheeler, M., Laubenbacher, R., & Mehrad, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.06.606866
Adult sickle cell disease and SARS-CoV-2: an increasingly common comorbidity for a rare disease
Boggan, M., Edwards, C. L., Meek, J., Wood, M., Bryson, W. J., Sollers, J. J., Parker, D. O., Barker, C. S., Miller, J., Downey, B., et al. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1701
Sickle Cell Anemia Its Epidemiology, Pathophysiology, Nutraceuticals Role: A Review
Kumar, A., Shalini, S., Yuvraj, Srinandhinidevi, K. M., Chapkanade, P. S., Nisha, K. B., Machhi, D. A., Sinha, S., Santosh Kumar, S. R., & Khongshei, R. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.3.4.12
Mohammadkarimi, V., Dehghani, M., Rast, M., & Amini, M. (2024) · Shiraz E-Medical Journal · doi:10.5812/semj-145771
Parrow, N. L., Doherty, J. M., Conrey, A. K., Thein, S. L., & Fleming, R. E. (2024) · Advances in Hematology · doi:10.1155/ah/9872440
Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis
Willen, S. M., Brunson, A. M., Adesina, O., Oluwole, O. B., & Wun, T. (2024) · American Journal of Hematology · doi:10.1002/ajh.70459
Lareef, I., & Sosa, I. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-75810-2_17
Márquez-Vega, I. C., Mata-Rosas, J. E., & Hernández-Monjaraz, B. (2024) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2024.6.2.5
Yamantürk, Y. Y., Özdöl, Ç., Esenboğa, K., & Uludağ, D. M. G. (2025) · Heart and Vessels · doi:10.1007/s00380-026-02684-1
Role of 5.8S rRNA in Zebrafish and Human Blood Coagulation
Alharbi, A. H. M. (2020) · doi:10.12794/metadc1752329
Sato, M. A., Chess‐Williams, R., & Aronsson, P. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1576452
Nakagawa, A., Morwood, K., Johnson, K., Berra, L. M., Boal, L. H., Azar, S., Huang, M., Heeney, M. M., Bloch, D. B., & Ichinose, F. (2025) · ACS Omega · doi:10.1021/acsomega.4c11077 · Cited by 1
Increased serum YKL-40 levels in children with sickle cell disease
Akbey, V., Ünal, S., Tezol, Ö., Taşdelen, B., Balcı, Ş., & Karahan, F. (2025) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2025.4805
Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease
Mohieldin, A. M., Spencer, M., Bernal, C., Fadol, W. B., Gupta, A., Thirugnanam, K., Delahunty, C. M., Nunez, F., Pan, A. Y., Brandow, A. M., et al. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00168
Nunez, F. J., Mohieldin, A. M., Pan, A. Y., Palecek, S. P., Zennadi, R., Ramchandran, R., Rarick, K. R., & Nauli, S. M. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251338961
Azizieh, F. Y., Raghupathy, R., Gupta, R., Zahra, A., Al‐Abboh, H., Alsahhaf, H., Fatima, R., & Adekile, A. D. (2025) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2025.100462
Machine Learning-Based Identification of Sickle Cell Disease Subphenotypes in Clinical Trial DataPreprint
Xiao, W., Oneal, P. A., Wang, M., Mehta, N. H., Liu, Q., Zhang, R., Perrine, S. P., & Ryan, Q. C. (2025) · medRxiv · doi:10.1101/2025.06.01.25328537
Envolvimento da angiopoietina-2 na nefropatia falciforme: uma revisão narrativa
Nascimento, E. S., & Lemes, R. P. G. (2025) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e20364.2025
End organ damage in sickle cell disease, a tertiary care hospital experience in Pakistan
Urooj, H., & Moiz, B. (2025) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2025.102104
Assessment of pulmonary hypertension in patients with sickle cell disease
Galal, A. M. M., Barakett, N., & Cheikhrouhou, I. (2025) · Egyptian Journal of Bronchology · doi:10.1186/s43168-025-00421-2
3d-Printed Hydroxyurea for Pediatric Use: Toward Safer and Personalized Drug AdministrationPreprint
Laverdière, J., Bendicho‐Lavilla, C., Mahrouche, L., Friciu, M., Pastore, Y. D., Leclair, G., Basit, A. W., Goyanes, Á., & Roullin, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5336353
Saha, P., Jha, R., Yasmin, A., Passi, A., Jindal, S., & Goyal, K. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03445-x
Pulmonary Hypertension in Sickle Cell Disease: A Case Series
Pokima, N., Gill, S., Moradi, R., Thida, A. M., & Muthu, J. (2025) · Cureus · doi:10.7759/cureus.89012
Machine Learning-Based Identification of Sickle Cell Disease Subphenotypes in Clinical Trial DataPreprint
Ryan, Q. C., Xiao, W., Oneal, P. A., Wang, M., Mehta, N., Liu, Q., Zhang, R., & Perrine, S. P. (2025) · Research Square · doi:10.21203/rs.3.rs-6770839/v1
Testosterone and Sickle Cell Disease
Musicki, B., & Burnett, A. L. “. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_33
HCAR2 the rescue: sensing heme, steering inflammation
Liu, Y., & Yazdanbakhsh, K. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016946
Sankhi, S., Tharu, B. K., Chaudhary, N. K., Yadav, S., Tamang, R., & Marasine, N. R. (2025) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580251371877
Anti-sickling efficacy and safety of Sailin-HbS, an indigenous Ayurvedic formulation
Bhatt, S., Bhansali, A., Rajesh, A. S., Meher, S., Jena, R. K., Dash, B. P., Panda, P. K., Gupta, K., & Kundu, S. (2025) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2025.102956
Morakis, M. M., Huang, L., McKay, G. N., Lanzkron, S., Pecker, L. H., & Durr, N. J. (2025) · medRxiv · doi:10.1101/2025.09.27.25336804
Sustained expression of hemopexin in an animal model of sickle cell anemia
de Lima, F., Moraes, C. R. P., Borba-Junior, I. T., Assalin, H. B., Saad, M. J. A., Costa, F. F., & Paula, E. V. D. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2025.100115
Heme-mediated Tau phosphorylation drives neurocognitive responses in sickle cell disease
Hu, X., Lenhart, S. C., Foley, L. M., Sekar, N., Mondal, P., Alagbe, A. E., Wang, H., Hitchens, T. K., Ghosh, S., Novelli, E. M., et al. (2025) · Blood Red Cells & Iron · doi:10.1016/j.brci.2025.100041
Isolation and Resistance Pattern of Bacteria from Infected Corneal Ulcer Patients in Human
Md. Anamul Haq, M. M. H. (2021) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/19.3.83-89
Hernández, C. A., Traets, M. J. M., van Solinge, W. W., Rijneveld, A. W., Kaestner, L., John, T. D., Nur, E., Biemond, B. J., Kuypers, F. A., van Beers, E. J., et al. (2025) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2025.102967
Hulı́ková, A., Wang, Z., Broomfield, H., Robinson, J., Healy, M., Figueroa, R. H., Gamboa, D., Torres, K., Ammanath, G., Hartono, D., et al. (2025) · Blood Global Hematology · doi:10.1016/j.bglo.2025.100058
Liu, Y., Zhu, Y., Jiang, C., Su, Z., Yan, Y., Feng, B., Wen, M., Zhang, Y., Wang, X., Xu, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26554715
Fang, F., Hazegh, K. E., Mast, A. E., Triulzi, D., Spencer, B. R., Gladwin, M. T., Busch, M. P., Kanias, T., & Page, G. P. (2022) · Figshare · doi:10.6084/m9.figshare.19408085
Self-citationMatsuo, M., Doi, T., Katsuki, M., Yoshimura, Y., Ito, H., Fukahara, K., Yoshimura, N., & Yamazaki, M. (2024) · Figshare · doi:10.6084/m9.figshare.26580737
Módolo, G. P., Luvizutto, G. J., Filho, P. T. H., Braga, G. P., Bazan, S. G. Z., Ferreira, N. C., de Souza, J. T., Winckler, F. C., Macedo de Freitas, C. C., Hokama, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20164714
Argueta, D. A., Garcia, N. R., Tagne, A. M., Piomelli, D., & Gupta, K. (2026) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2026.100136
Jones, B., Miller, J., Lopez, A. S. M., Norris, J. L., Green, C., Sollers, J. J., III, Wood, M., Bryson, W. J., Sollers, J. J., III, Barker, C. S., et al. (2026) · Journal of the National Medical Association · doi:10.1016/j.jnma.2025.12.007
Whole Blood Transcriptomic Analysis of Sickle Cell Trait
Johnson, M., Cai, Y., Vasconcelos, A. G., Orchard, P., Auer, P. L., Lettre, G., Wen, J., Franceschini, N., Kooperberg, C. L., Sun, W., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70114
Chen, R., Han, N., Xiao, Q., Hou, G., Liu, S., Zhou, S., Zhang, Q., & Lv, H. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004812
Platt, M. O., Lee, H. S., & Hatoum, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_4
Musmar, B., Roy, J. M., Abdalrazeq, H., Yacoub, C., Adeeb, N., Fuleihan, A. A., Koduri, S., Baldassari, M. P., Lan, M., Patel, P. D., et al. (2026) · Translational Stroke Research · doi:10.1007/s12975-026-01412-1
Steinberg, M. H. (2026) · Springer eBooks · doi:10.1007/978-3-031-96019-2_34
Self-citationVascular Geometry Drives Stroke Risk in Sickle Cell Disease
Liu, W., Kassasseya, C., Papamanolis, L., Nguyen, K., Garreau, M., Eckert, S., Luna, G. D., d’Humières, T., Pierrefeu, V. M. D. D., Arnaud, C., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70184
Ansong‐Ansongton, Y. O. N., Mohamed, K. A., Bamac, D. Z., Horneman, H. F., Usac, F., Goreke, U., Alejandro, M., Soupène, E., Giannikopoulos, P., Nguyen, D. N., et al. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100058
Zaidi, S. Z. H., Vasudev, M. M., & Mavathur, R. (2026) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2026.100152
Emerging concepts in sickle cell disease acute chest syndrome
Gillespie, M. L., King, T., Cohen, R. T., Willen, S. M., Koya, A. I., Ruhl, A. P., & Kopp, B. T. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100060
Al-Ansari, R. Y., Elsheikh, N. B. A., Sahal, N., Alghamdi, M. A., Alshamrani, A., Alharbi, A. F., Alamri, R. I., Arulanantham, Z. J., Abdellatif, M. F., Aljamily, M. I., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8925505/v1
Chauhan, W., Fernandez, O., Shah, N., Pan, A., Rarick, K. R., Mohieldin, A. M., Nauli, S. M., Palecek, S. P., Ramchandran, R., & Zennadi, R. (2026) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoag016
PVR ≥1.5 WU in sickle cell disease: a universal prognostic marker or context-dependent finding?
Guo, S., Yao, Y., & Zhou, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag130
Exploring the latest emerging drugs for the treatment of sickle cell disease
Cannas, G. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2650178
Plasma heme pool compartmentalization is linked to pathophysiology in Sickle Cell Disease
Saxenhofer, M., Couto, D., Perez, S. M., Illi, M., Brodard, J., Njue, L. M., Chanias, I., Medri, C., Tsilimidos, G., Hadorn, N., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343527
Self-citationImpact of mechanical and oxidative stress on red blood cell properties in sickle cell disease
Lizarralde-Iragorri, M. A. (2018) · theses.fr (ABES) · doi:10.70675/d9c8d09dz1910z4e84z8ac2zdeb3953d952c
Lalanne‐Mistrih, M. (2019) · theses.fr (ABES) · doi:10.70675/aa735006z75a2z4c63zaa8cz82d11d170a47
Skinner, S. C. (2018) · theses.fr (ABES) · doi:10.70675/bad1111dz9f48z4cb3z82b1z01030b2c1ced
Immunogénétique en drépanocytose
Tozatto‐Maio, K. (2019) · theses.fr (ABES) · doi:10.70675/92d0b87bz2afdz446dza5bdze7321b6555d7
Modulation et rôle des paramètres hémorhéologiques dans la physiopathologie de la drépanocytose
Griffon, C. (2018) · theses.fr (ABES) · doi:10.70675/ad2b1266zad9fz4070z9fd7z1abcbdd2b38f
Mast cells, basophils and substance P in sickle cell disease
Allali, S. (2019) · theses.fr (ABES) · doi:10.70675/828c9877z8b20z487ezacb6z3ea67e4f5d73
Anomalies de la mitophagie au cours de la maturation érythroïde dans la drépanocytose
Martino, S. (2020) · theses.fr (ABES) · doi:10.70675/a131d6c1z5236z45e9z93e3zec879bb0d4ff
Stauffer, É. (2021) · doi:10.70675/65143700zc6e4z45e0z8273z3a91bb022450
New mechanisms involved in the modulation of sickle red blood cells rheology and senescence
Esperti, S. (2023) · theses.fr (ABES) · doi:10.70675/57fbff51z05a3z4c75zbaedz4914780911db
Alwaheed, A., Alqatari, S. G., Alalwan, S. J., Alnufaily, D. A., Almuslim, M. M., Aldossari, M. L., Alabdullah, M. M., Alzahrani, S. A., Jama, A. A., Kutbi, H. A., et al. (2026) · Medicina · doi:10.3390/medicina62040774
DCN1 inhibitor induces fetal hemoglobin through self-limited regulation of CUL3 neddylationPreprint
Miller, S. A., Monti, A., Zhou, E. H., Lin, C. H. S., Lynch, O., Mukherjee, S., Hei, C., Nicewonger, R., Diner, C., Macias-Garcia, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.720177
Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
Lucas, D., Munoz, C., Palmer, A. F., & Cabrales, P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119439
Javed, D., Rai, A. K., Bansal, S., Yadav, B., Shrivastava, M., Goel, G., Kumar, A., Kumar, S., Ahmad, A., Singhal, R., et al. (2026) · JMIR Research Protocols · doi:10.2196/79603 · Cited by 1
Metadata
- Authors
- Kato, G. J., Steinberg, M. H., & Gladwin, M. T.
- Affiliations
- University of Pittsburgh (US)
- Boston University (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-03-01
- Volume
- 127
- Issue
- 3
- Pages
- 750-760
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5330745
- OpenAlex
- W2592339311
- Semantic Scholar
- 0c9beb4e3a557982862ac3ec381a89baab12ceae
- Cited by
- 748
- References
- 193
- Citations by year
- 2026: 90 · 2025: 81 · 2024: 76 · 2023: 65 · 2022: 116 · 2021: 81 · 2020: 87 · 2019: 76 · 2018: 53 · 2017: 21
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Patient-Centered Outcomes Research Institute
- University of Pittsburgh
- Hemophilia Center of Western Pennsylvania
- National Institutes of Health (HL098032)
- National Heart, Lung, and Blood Institute (R01HL087681, R01HL068970, P01HL103455, RC2HL101212, R01HL121386, U01HL107443, T32HL007501, R01HL125886, R01HL098032, T32HL110849)
- National Institute on Minority Health and Health Disparities (R01MD009162)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Keywords
- intravascular hemolysis, sickle cell disease, free hemoglobin, nitric oxide, methemoglobin, heme, arginase-1, asymmetric dimethylarginine, adenine nucleotides, pulmonary hypertension, inflammation
- MeSH terms
- Anemia, Sickle Cell, Hemolysis, Humans, Methemoglobin, Nitric Oxide, Vascular Diseases, Vasomotor System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
